| 15.69 0.04 (0.26%) | 09-12 11:48 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 19.33 | 1-year : | 22.57 |
| Resists | First : | 16.54 | Second : | 19.33 |
| Pivot price | 15.4  |
|||
| Supports | First : | 13.06 | Second : | 10.9 |
| MAs | MA(5) : | 15.61 |
MA(20) : | 15.14 |
| MA(100) : | 13.86 |
MA(250) : | 9.33 |
|
| MACD | MACD : | 0.6 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 69.8 |
D(3) : | 70.9 |
| RSI | RSI(14): 59.9 |
|||
| 52-week | High : | 19.1 | Low : | 2.09 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ CATX ] has closed below upper band by 29.1%. Bollinger Bands are 55% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 15.88 - 15.96 | 15.96 - 16.03 |
| Low: | 15.02 - 15.11 | 15.11 - 15.19 |
| Close: | 15.49 - 15.66 | 15.66 - 15.79 |
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
Tue, 10 Sep 2024
Perspective Therapeutics Presents at the World Molecular Imaging Congress 2024 - StockTitan
Mon, 09 Sep 2024
Perspective Therapeutics (NYSE:CATX) Earns "Overweight" Rating from Cantor Fitzgerald - MarketBeat
Thu, 05 Sep 2024
Perspective gets FDA fast track status for radiopharmaceutical VMT01 (NYSE:CATX) - Seeking Alpha
Tue, 03 Sep 2024
Perspective Therapeutics (NYSE:CATX) Stock Rating Reaffirmed by Cantor Fitzgerald - MarketBeat
Fri, 30 Aug 2024
Perspective Therapeutics announces executive transition - Investing.com
Fri, 30 Aug 2024
Mark Austin Steps Down from Executive Roles at Perspective Therapeutics - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 281 (M) |
| Shares Float | 203 (M) |
| Held by Insiders | 22.3 (%) |
| Held by Institutions | 15 (%) |
| Shares Short | 1,840 (K) |
| Shares Short P.Month | 2,050 (K) |
| EPS | -0.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.34 |
| Profit Margin | 0 % |
| Operating Margin | -482.2 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 27.2 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.02 |
| EBITDA (p.s.) | -0.15 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -34 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -262.67 |
| PEG Ratio | 0 |
| Price to Book value | 45.02 |
| Price to Sales | 700.75 |
| Price to Cash Flow | -130.06 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|